Compare Tango Therapeutics Inc. (TNGX) vs XP Inc. Class A Common Stock (XP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs XP Inc. Class A Common Stock — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while XP Inc. Class A Common Stock trades at $30.06 (market cap $15.93B). The key difference: XP Inc. Class A Common Stock is far larger — about 4.2× Tango Therapeutics Inc.'s market cap, and XP Inc. Class A Common Stock pays a 0.64% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and XP Inc. Class A Common Stock for 5 Days on average.
| TNGX | XP | |
|---|---|---|
Market Cap | $3.75B | $15.93B |
Volume | 9,619,106 | 10,243,374 |
Sector | Health | Financials |
52-Week High | $32.90 | $32.60 |
52-Week Low | $7.50 | $14.94 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $2.77B | $25.63B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
XP Inc. trades at $31.38, down 3.74% today but remains near recent highs. The stock shows strong fundamental performance with 63.12% net income margin and 22.58% ROE, supported by consistent earnings beats in recent quarters. Technical indicators show mixed signals with bullish moving averages but overbought RSI readings. Analyst sentiment remains strongly positive with 80% buy ratings and price targets suggesting significant upside potential from current levels.
The outlook for XP remains favorable given its robust profitability metrics and growing revenue base, though investors should monitor competitive pressures and market volatility. The company's strong cash flow generation and institutional support provide stability, while technical overbought conditions suggest potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About XP Inc. Class A Common Stock
XP Inc. provides investment products and financial services in Brazil. Its platform includes brokerage, investment funds, fixed-income products, banking, insurance, and retirement solutions.
Read more on XP →
